5446442026-01-012026-03-315446442026-03-315446442025-03-315446442025-04-012026-03-315446442026-01-012026-03-31in-capmkt:OtherExpenses1Member5446442025-04-012026-03-31in-capmkt:OtherExpenses1Member5446442026-03-31OtherNoncurrentFinancialAssetsDomain15446442026-03-31OtherNoncurrentAssetsDomain15446442026-03-31OtherCurrentFinancialAssetsDomain15446442026-03-31OtherCurrentAssetsDomain15446442026-03-31OtherNoncurrentFinancialLiabilitiesDomain15446442026-03-31OtherCurrentFinancialLiabilitiesDomain15446442026-03-31OtherCurrentLiabilitiesDomain15446442026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544644CORONANOTLISTEDINE02ZQ01018CORONA REMEDIES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-112026-04-30INRCroresQuarterlyFourth quarterSingle segmentPHARMACEUTICALS2026-05-1114:30:002026-05-1116:00:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated3530900000411000003572000000277300000463400000-783000001066300000138000001029000001182000000302740000054460000028000005474000004230000051800000941000000453300000000045330000067000004600000004533000006700000611600000107.417.41007.417.41Notes to Consolidated Financial Results for the Quarter and Year ended 31 March 2026 : <BR> <BR> 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders. <BR> <BR> 2 The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 11 May 2026. <BR> <BR> 3 These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended. <BR> <BR> 4 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures with respect to the full financial year for the year ended 31 March 2025 and audited special purpose interim financial statements for the nine months period ended 31 December 2024 which were prepared for IPO filings and have not been reviewed by the statutory auditors. <BR> <BR> 5 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended 31 December 2025 which were subjected to limited review. <BR> <BR> 6 One time impact of New Labour Codes : <BR> On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the year ended 31 March 2026. <BR> The incremental impact consisting of gratuity of Rs.13.60 crores and long-term compensated absences of Rs.5.50 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. <BR> <BR> 7 As at 31 March 2026, the Company held fixed deposits aggregating to Rs. 155.70 Crores (comprising Rs. 128.70 Crores under other non-current financial assets and Rs. 27.00 Crores under bank balances other than cash and cash equivalents), against which overdraft facilities amounting to Rs. 126.86 Crores were availed and disclosed under short-term borrowings. <BR> <BR> 8 The Board of Directors have recommended dividend of Rs.10/- per fully paid up equity share of Rs.10/- each for financial year ended 31 March 2026 on outstanding paid up share capital of the Company as on date, in its board meeting held on 11 May 2026, subject to approval of the shareholders at Annual General Meeting (AGM) of the Company. <BR> <BR> 9 The Company and its associate has only one reportable business segment i.e. ‘Pharmaceuticals’. <BR> <BR> 2025-04-012026-03-31AuditedConsolidated140318000001065000001413830000010351000001503800000705000004030200000697000003787000004457800000115458000002592500000-1883000002404200000514800000382000005530000000185120000000001851200000110000018523000001851200000110000061160000010030.2730.270030.2730.27Other Expenses1182000000Other Expenses4457800000291140000014312000000262830000026120000017000001000001298700000130050000035700000856830000012500000000145550000018300000422900000260000030000001902300000330800000348310000012051400000611600000685700000074686000007468600000018880000018880000066070000012160000097110000014286000009850000013722000001470700000228300000312760000069900000330400000838000003611700000458280000012051400000other financial assets1298700000other non current assets35700000Other financial assets3000000Other current assets330800000Other non-current financial liabilities188800000Other current financial liabilities228300000Other current liabilities699000006970000052100000-2621000000-1427000000400000236000000371000000-30300000037870000002495000000137000000-125000000706000000-70000000816000000-27000003848000002789000000000494200000022948000000000000054000001741400000000000000000000000706000000-896100000-25615000000000044710000000116160000036000000000526000000-49100000252800000-139000000-139000003220000018300000-6700000-11000000067000001100000AuditedtrueDeloitte Haskins & Sells LLPtrue2027-07-31